Nima Melzer

Nuernberg, BY, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Secukinumab Reduces Psoriasis-associated Pruritus and Regenerates the Cutaneous Nerve Architecture: Results from PSORITUS a Doubleblind, Placebo-controlled, Randomized Withdrawal Phase IIIb Study.

Secukinumab Reduces Psoriasis-associated Pruritus and Regenerates the Cutaneous Nerve Architecture: Results from PSORITUS a Doubleblind, Placebo-controlled, Randomized Withdrawal Phase IIIb Study.

Journal: Acta dermato-venereologica

Published: May 10, 2024

The socio-economic burden of H1-antihistamine-refractory chronic spontaneous urticaria in Germany.

The socio-economic burden of H1-antihistamine-refractory chronic spontaneous urticaria in Germany.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: November 13, 2023

The Societal Economic Impact of Secukinumab in First-Line Treatment of Moderate to Severe Plaque Psoriasis in Germany: An Open-Cohort Simulation.

The Societal Economic Impact of Secukinumab in First-Line Treatment of Moderate to Severe Plaque Psoriasis in Germany: An Open-Cohort Simulation.

Journal: PharmacoEconomics - open

Published: September 16, 2021

Biologic Treatment in Combination with Lifestyle Intervention in Moderate to Severe Plaque Psoriasis and Concomitant Metabolic Syndrome: Rationale and Methodology of the METABOLyx Randomized Controlled Clinical Trial.

Biologic Treatment in Combination with Lifestyle Intervention in Moderate to Severe Plaque Psoriasis and Concomitant Metabolic Syndrome: Rationale and Methodology of the METABOLyx Randomized Controlled Clinical Trial.

Journal: Nutrients

Published: June 29, 2021

ERAPSO: Revealing the High Burden of Obesity in German Psoriasis Patients.

ERAPSO: Revealing the High Burden of Obesity in German Psoriasis Patients.

Journal: Dermatology and therapy

Published: May 22, 2019

Impact of Secukinumab on Endothelial Dysfunction and Other Cardiovascular Disease Parameters in Psoriasis Patients over 52 Weeks.

Impact of Secukinumab on Endothelial Dysfunction and Other Cardiovascular Disease Parameters in Psoriasis Patients over 52 Weeks.

Journal: The Journal of investigative dermatology

Published: July 01, 2018

Pharmacokinetics of Certoparin During In Vitro and In Vivo Dialysis.

Pharmacokinetics of Certoparin During In Vitro and In Vivo Dialysis.

Journal: Artificial organs

Published: April 23, 2015

Treatment of deep vein thrombosis in patients with pulmonary embolism: subgroup analysis on the efficacy and safety of certoparin vs. unfractionated heparin.

Treatment of deep vein thrombosis in patients with pulmonary embolism: subgroup analysis on the efficacy and safety of certoparin vs. unfractionated heparin.

Journal: Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis

Published: July 09, 2014

Effects of 8,000 IU aXa long-term prophylaxis with certoparin on the incidence of hyperkalemia in patients with coronary heart disease--a post-hoc analysis of the PARAT trial.

Effects of 8,000 IU aXa long-term prophylaxis with certoparin on the incidence of hyperkalemia in patients with coronary heart disease--a post-hoc analysis of the PARAT trial.

Journal: BMC research notes

Published: June 10, 2014

Perioperative management of anticoagulation

Perioperative management of anticoagulation

Journal: Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen

Published: May 15, 2014

Prospective, non-interventional study on the real-world use of certoparin in daily practice--the PROMEMBER study.

Prospective, non-interventional study on the real-world use of certoparin in daily practice--the PROMEMBER study.

Journal: Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis

Published: June 15, 2012

A multi-center, prospective, open-label, 8-week study of certoparin for anticoagulation during maintenance hemodialysis--the membrane study.

A multi-center, prospective, open-label, 8-week study of certoparin for anticoagulation during maintenance hemodialysis--the membrane study.

Journal: BMC nephrology

Published: March 21, 2012

Showing 1-12 of 15

Last Updated: 09/26/2026